Releases
DARE
0.4902
-10.71%
-0.0588
  • All
  • Financials
  • Insiders
More
Webull provides the latest Dare Bioscience Inc (DARE) stock and general news. This information may help you make smarter investment decisions.
About DARE
Dare Bioscience, Inc. is a biopharmaceutical company. The Company is engaged in identifying, developing, and marketing a portfolio of differentiated therapies that prioritize women's health and well-being, primarily in the areas of contraception, vaginal health, reproductive health, menopause, sexual health and fertility. Its first product, XACIATO, is a clindamycin phosphate vaginal gel used for the treatment of bacterial vaginosis in female patients 12 years of age and older. Its pipeline includes various other clinical-stage programs, such as Ovaprene, Sildenafil Cream 3.6%, DARE-HRT1, DARE-VVA1, DARE-FRT1 and DARE-PTB1. Its pre-clinical-stage programs include DARE-LARC1, DARE-GML, DARE-LBT, and DARE-RH1. Ovaprene is an investigational hormone-free monthly intravaginal contraceptive. Sildenafil Cream 3.6% is a proprietary cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder (FSAD).